These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36458459)

  • 1. Significance of regulatory T cells in cancer immunology and immunotherapy.
    Sugiyama D; Hinohara K; Nishikawa H
    Exp Dermatol; 2023 Mar; 32(3):256-263. PubMed ID: 36458459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
    Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
    Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
    Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
    J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
    Ohue Y; Nishikawa H
    Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
    Togashi Y; Shitara K; Nishikawa H
    Nat Rev Clin Oncol; 2019 Jun; 16(6):356-371. PubMed ID: 30705439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells.
    Satoh K; Kobayashi Y; Fujimaki K; Hayashi S; Ishida S; Sugiyama D; Sato T; Lim K; Miyamoto M; Kozuma S; Kadokura M; Wakita K; Hata M; Hirahara K; Amano M; Watanabe I; Okamoto A; Tuettenberg A; Jonuleit H; Tanemura A; Maruyama S; Agatsuma T; Wada T; Nishikawa H
    Int Immunol; 2021 Jul; 33(8):435-446. PubMed ID: 34235533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redox modulation with a perfluorocarbon nanoparticle to reverse Treg-mediated immunosuppression and enhance anti-tumor immunity.
    Li Z; Deng Y; Sun H; Tan C; Li H; Mo F; Wang Y; Li J; Zhou Z; Sun M
    J Control Release; 2023 Jun; 358():579-590. PubMed ID: 37172908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine.
    Kumagai S; Itahashi K; Nishikawa H
    Nat Rev Clin Oncol; 2024 May; 21(5):337-353. PubMed ID: 38424196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
    Aristin Revilla S; Kranenburg O; Coffer PJ
    Front Immunol; 2022; 13():903564. PubMed ID: 35874729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
    Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of Cancer by Targeting Regulatory T cells.
    Chen BJ; Zhao JW; Zhang DH; Zheng AH; Wu GQ
    Int Immunopharmacol; 2022 Mar; 104():108469. PubMed ID: 35008005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
    Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting regulatory T cells in tumors.
    Liu C; Workman CJ; Vignali DA
    FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T-cell development in the tumor microenvironment.
    Itahashi K; Irie T; Nishikawa H
    Eur J Immunol; 2022 Aug; 52(8):1216-1227. PubMed ID: 35879813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic advantages of regulatory T cells dictated by cancer cells.
    Kondo M; Kumagai S; Nishikawa H
    Int Immunol; 2024 Feb; 36(2):75-86. PubMed ID: 37837615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.